Pampee Young

Vanderbilt investigators have now discovered that, in contrast to prevailing dogma, fibroblasts are not all alike; instead, they have distinctive functions following tissue injury. Read More

Vanderbilt’s Pampee Young, MD, PhD, has been named chief medical officer of the American Red Cross. Read More

During a deployment as a military surgeon more than a decade ago, Vanderbilt University Medical Center’s Tim Nunez, M.D., felt ill prepared to perform complex trauma surgeries for an Iraqi family caught in a fire fight, but he's now committed to helping military personnel become better trained for these types of emergencies. Read More

Drugs that inhibit the Wnt signaling pathway can regenerate injured skin and may be useful in treating fibromatosis, degenerative joint disease and cancer. Read More

A metabolic change in adult stem cells makes them less “fit” for regenerative heart therapies, suggesting that strategies to prevent this response may boost the therapeutic usefulness of the cells. Read More

Pediatric patients have a significantly higher incidence of transfusion reactions compared to adults, according to a study by Vanderbilt University researchers. Read More

A newly identified “atheroprotective” gene is a tool for exploring plaque pathophysiology and may be a good target for therapies to slow atherosclerosis progression. Read More

A factor produced by most malignant cells can both promote and inhibit tumor growth – an insight that is critical to using cancer drugs developed to block this factor. Read More

Pampee Young, associate professor of pathology, microbiology and immunology, is one of many U.S. scientists whose research funding will be compromised by the impending enactment of the Budget Control Act (the "fiscal cliff") if Congress does not resolve the budget impasse. Read More

Enhancing stem cell survival is key to improving cell-based therapies for regenerative medicine, and a new drug could help. Read More